After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...
During his presentation at the J.P. Morgan Healthcare Conference last week, Incyte CEO Hervé Hoppenot took investors on a ...
Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...
CDMO Joinn Biologics snaps up China biologics plant from Lonza in push to tackle Asia-Pacific market
With the purchase of a former Lonza biologics plant now in the books, San Francisco-based CDMO Joinn Biologics is expanding from one Bay Area to another. | CDMO Joinn Biologics has completed its ...
As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...
Meridian Medical Technologies, a unit of CDMO Kindeva, snared a $129 million contract to supply the United States with the ...
After revenue boomed for biopharma manufacturers during the COVID pandemic, sales have stagnated for several CDMO giants, ...
Fosun International’s proposed buyout of its partially owned subsidiary, Shanghai Henlius Biotech, has been quashed, with the ...
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...
Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a ...
Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...
Xeris Pharmaceuticals has teamed up with the American Diabetes Association (ADA) to raise awareness of the importance of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback